Indian AI Cancer Care Platform Spotlighted at BRICS Summit
iOncology.ai, developed by AIIMS and C-DAC, gains global recognition at BRICS Summit for its potential to transform cancer care in emerging economies.
An innovative Indian artificial intelligence platform, iOncology.ai, designed to revolutionize cancer care, was highlighted at the recent BRICS Summit. This platform, developed by the All India Institute of Medical Sciences (AIIMS), New Delhi, and the Centre for Development of Advanced Computing (C-DAC), Pune, is featured in a special issue of the BRICS Health Journal, underscoring its significance in the realm of global health technology.
AI-Driven Cancer Care Innovation
iOncology.ai aims to integrate various aspects of cancer-related clinical data to enhance early detection, risk stratification, treatment planning, and patient-data management. The platform is a collaborative effort supported by the Ministry of Electronics and Information Technology, reflecting India's commitment to leveraging technology in healthcare.
The journal review titled “Transforming cancer care in emerging economies: India’s AI innovation,” authored by Ashok Sharma and his team from AIIMS and C-DAC, explores the potential of AI to improve cancer screening and diagnosis. It highlights the platform's ongoing pilot-stage clinical validation and its potential to address disparities in cancer care across the Global South.
Addressing Global Cancer Care Disparities
Dr. Ashok Sharma emphasized the platform's potential to bridge cancer-care gaps in emerging economies during a discussion with the Times of India. He pointed out the importance of BRICS collaboration in enhancing cancer prevention, early diagnosis, and treatment through interoperable solutions tailored to local needs. The journal review notes that BRICS countries, home to over 40% of the global population, face significant challenges with 9 million new cancer cases annually.
iOncology.ai is positioned within India's expanding digital health infrastructure, which includes initiatives like the Ayushman Bharat Digital Mission. The platform utilizes Indian clinical, radiological, and histopathological datasets and plans to incorporate genetic data, aiming for integration with electronic health-record systems.
Future Prospects and Validation
Despite its promising design, iOncology.ai is still undergoing evaluation in research settings. No peer-reviewed evidence has yet confirmed its diagnostic accuracy or clinical utility. Prospective multicenter validation will be essential before the platform can be widely adopted in clinical environments.
The initiative underscores India's potential to lead in digital health innovations, addressing critical healthcare challenges in resource-constrained settings. As iOncology.ai progresses through validation phases, it represents a significant step toward more equitable cancer care in emerging economies.